Success Metrics

Clinical Success Rate
100.0%

Based on 11 completed trials

Completion Rate
100%(11/11)
Active Trials
0(0%)
Results Posted
82%(9 trials)

Phase Distribution

Ph phase_3
3
25%
Ph phase_4
1
8%
Ph phase_1
1
8%
Ph phase_2
3
25%

Phase Distribution

1

Early Stage

3

Mid Stage

4

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
1(12.5%)
Phase 2Efficacy & side effects
3(37.5%)
Phase 3Large-scale testing
3(37.5%)
Phase 4Post-market surveillance
1(12.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

11 of 11 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

12

all time

Status Distribution
Completed(11)
Other(1)

Detailed Status

Completed11
unknown1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (12.5%)
Phase 23 (37.5%)
Phase 33 (37.5%)
Phase 41 (12.5%)

Trials by Status

completed1192%
unknown18%

Recent Activity

0 active trials
Showing 5 of 12
completed

A Study of MIRCERA in Participants With Chronic Kidney Disease Stage 3-4 and Not on Dialysis

NCT02567188
completedphase_3

Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects

NCT04707768
completedphase_3

A Study of Efepoetin Alfa in Treating Anaemia Associated With Chronic Kidney Diseases Patient

NCT04155125
completedphase_2

Ascertain the Optimal Starting Dose of Mircera Given Subcutaneously for Maintenance Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease on Dialysis or Not Yet on Dialysis.

NCT03552393
completedphase_2

Comparative Study of the Efficacy and Safety of BCD-131 and Mircera in Treatment of Anemia in CKD Patients on Dialysis

NCT03519243
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT02567188

A Study of MIRCERA in Participants With Chronic Kidney Disease Stage 3-4 and Not on Dialysis

Completed
NCT04707768Phase 3

Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects

Completed
NCT04155125Phase 3

A Study of Efepoetin Alfa in Treating Anaemia Associated With Chronic Kidney Diseases Patient

Completed
NCT03552393Phase 2

Ascertain the Optimal Starting Dose of Mircera Given Subcutaneously for Maintenance Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease on Dialysis or Not Yet on Dialysis.

Completed
NCT03519243Phase 2

Comparative Study of the Efficacy and Safety of BCD-131 and Mircera in Treatment of Anemia in CKD Patients on Dialysis

Completed
NCT02731469Phase 1

Study of Pharmacokinetics, Pharmacodynamics, Safety of BCD-131 Compared to Mircera and Aranesp in Healthy Volunteers

Completed
NCT02044653Phase 2

Study to Evaluate the Efficacy and Safety of GX-E2 in the Anemic Patients Diagnosed With Chronic Kidney Disease (CKD)

Completed
NCT01417377

An Observational Study of Mircera (Methoxy Polyethylene Glycol-epoetin Beta) in Anemic Patients With Chronic Kidney Disease (NORM)

Completed
NCT02263833

An Observational, Prospective, Safety Study of Mircera (Monopegylated Epoetin Beta) in Clinical Practice

Completed
NCT02540213

Observational Study of MIRCERA in Users of Self-Application and Multidose Systems

Completed
NCT01807481Phase 4

Phase IV Study to Evaluate the Efficacy and Safety of Mircera in PD

Unknown
NCT00442702Phase 3

A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.

Completed

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12